Yahoo · Nov 12, 2026
Actinium Pharmaceuticals to Host KOL Webinar on ATNM-400, a First-in-Class HER3-Targeted Alpha Radiotherapy
Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) ("Actinium" or the "Company"), a pioneer in the development of targeted radiotherapies, today announced that it will host a key opinion leader (KOL) webinar on Tuesday, December 1, 2026, at 8:00 a.m. ET to discuss the evolving treatment landscape in metastatic castration-resistant prostate cancer (mCRPC) and the potential of ATNM-400, its investigational, first-in-class, HER3-targeted Actinium-225 antibody radioconjugate.


